Abstract:63 Background: Chemoradiotherapy followed by radical surgery is standard treatment for patients with locally advanced rectal cancer (LARC). Short-course radiotherapy (SCRT), either with immediate or delayed surgery, provides similar oncological results compared with long-course radiotherapy with delayed surgery. Delayed surgery with the addition of neoadjuvant immunotherapy may bring better downstaging effect and minimize the risk of distant relapse. We conducted this single-arm phase 2 trial to investigate the efficacy and safety of SCRT combined with subsequent capecitabine and oxaliplatin (CAPOX) plus Camrelizumab (anti-PD-1 antibody) followed by delayed surgery in patients with LARC. Methods: Patients with histologically confirmed T3–4N0M0 or T1-4N+M0 rectal cancer, previously untreated disease, and ECOG performance status of 0-1, received SCRT (5×5 Gy) with subsequent two 21-day cycles of CAPOX (oxaliplatin 130 mg/m2 ivgtt, d1; capecitabine 1000 mg/m2 po bid, d1-14) plus Camrelizumab (200 mg iv drip, d1) after 1 week, followed by radical surgery after 1 week. Adjuvant therapy was decided by the investigator. The primary endpoint was pathological complete response (pCR) rate, defined as the absence of viable tumor cells in the primary tumor and lymph nodes. The study is ongoing to follow up the survival outcomes and obtain the results of next generation sequencing and PD-L1 expression. The data cutoff date was September 8, 2020. Results: From November 2019 to September 2020, a targeted number of patients (n = 29) were enrolled and are expected to complete the surgery by November 2020. The median age was 57 (range 31-73) years, 55% (16/29) of patients had ECOG performance status of 1, and the median distance from tumor to the anal verge was 5 (range, 1.9-9) cm. At data cutoff, 10 patients had undergone the surgery, with R0 resection rate of 100%. The pCR rate was 60% (6/10), including 56% (5/9) for those with mismatch repair-proficient, and 100% (1/1) for those with mismatch repair-deficient. Of 4 patients without pCR, 2 only received one cycle of CAPOX plus Camrelizumab due to the outbreak of COVID-19 in Wuhan, and 1 had signet-ring cell rectal carcinoma. At data cutoff, 20 patients had received at least one dose of Camrelizumab. Immune-related adverse events (irAEs) were all grade 1-2, and the most common irAE was reactive cutaneous capillary endothelial proliferation in 10 (50%) of 20 patients. Postoperative bleeding and infection occurred in 1 (10%) and 2 (20%) of 10 patients, respectively. No treatment-related death was observed. Conclusions: SCRT combined with subsequent CAPOX plus Camrelizumab followed by delayed surgery showed promising pCR rate with good tolerance in patients with LARC, regardless of the mismatch repair status, suggesting a candidate strategy for the neoadjuvant therapy. Clinical trial information: NCT04231552.

Neoadjuvant Chemotherapy with Capecitabine Combined with Oxaliplatin for Mid-Low Locally Advanced Rectal Cancer with Negative Mesorectal Fascia: Long-term Outcomes of a Prospective Trial (PKUCH-R03 Trial).

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Neoadjuvant Chemotherapy with CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.

Preoperative Radiotherapy Combined with Simultaneous Chemotherapy with Capecitabine Plus Oxaliplatin Versus Surgery Alone: A Single-Centered, Phase Ii Study in Patients with Mid/Low Rectal Cancer.

Total Neoadjuvant Treatment for MRI-stratified High-Risk Rectal Cancer: a Single-Center, Single-Arm, Prospective Phase II Trial (PKUCH-R02)

Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy with Concurrent Capecitabine for Locally Advanced Rectal Cancer

Efficacy of Neoadjuvant CapeOX/mFOLFOX6 Without Radiation for Patients with Baseline Resectable Mid-Low Locally Advanced Rectal Cancer.

Short-term outcomes of neoadjuvant chemotherapy with capecitabine plus oxaliplatin for patients with locally advanced rectal cancer followed by total or tumor-specific mesorectal excision with or without lateral pelvic lymph node dissection

Short-course Radiotherapy and Subsequent CAPOX Plus Camrelizumab Followed by Delayed Surgery for Locally Advanced Rectal Cancer:Short-Term Results of a Phase II Trial.

Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer.

Neoadjuvant Chemotherapy With Oxaliplatin And Capecitabine Versus Chemoradiation With Capecitabine For Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (Convert): Initial Results Of A Multicenter Randomised, Open-Label, Phase Iii Trial

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial

Total Neoadjuvant Treatment (CAPOX Plus Radiotherapy) for Patients with Locally Advanced Rectal Cancer with High Risk Factors: A Phase 2 Trial

Neoadjuvant Chemotherapy Alone with Mfolfoxiri in Locally Advanced Rectal Cancer: A Single-Arm Phase II Study.

Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study

Long-term Results of Postoperative Chemoradiation Therapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase III Trial.

Neoadjuvant Chemotherapy with Mfolfoxiri Alone for Ct4 and Fixed Ct3 Rectal Cancer: Results from a Single Arm Phase II Study (FORTUNE).

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.